Compare ALEMBIC PHARMA with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AJANTA PHARMA ALEMBIC PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 15.6 22.1 70.4% View Chart
P/BV x 3.9 3.8 101.7% View Chart
Dividend Yield % 1.0 0.9 106.4%  

Financials

 ALEMBIC PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
AJANTA PHARMA
Mar-19
ALEMBIC PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6641,422 46.7%   
Low Rs412898 45.9%   
Sales per share (Unadj.) Rs208.7233.5 89.4%  
Earnings per share (Unadj.) Rs31.044.0 70.5%  
Cash flow per share (Unadj.) Rs37.152.2 71.2%  
Dividends per share (Unadj.) Rs5.509.00 61.1%  
Dividend yield (eoy) %1.00.8 131.7%  
Book value per share (Unadj.) Rs144.2255.1 56.5%  
Shares outstanding (eoy) m188.5288.02 214.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.65.0 51.9%   
Avg P/E ratio x17.426.4 65.8%  
P/CF ratio (eoy) x14.522.2 65.2%  
Price / Book Value ratio x3.74.5 82.1%  
Dividend payout %17.720.5 86.7%   
Avg Mkt Cap Rs m101,461102,081 99.4%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m7,4674,307 173.4%   
Avg. sales/employee Rs ThNM3,022.6-  
Avg. wages/employee Rs ThNM633.4-  
Avg. net profit/employee Rs ThNM569.1-  
INCOME DATA
Net Sales Rs m39,34720,554 191.4%  
Other income Rs m94211 44.5%   
Total revenues Rs m39,44120,765 189.9%   
Gross profit Rs m8,7365,664 154.2%  
Depreciation Rs m1,152721 159.9%   
Interest Rs m18412 1,587.1%   
Profit before tax Rs m7,4935,143 145.7%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5681,273 123.1%   
Profit after tax Rs m5,8443,870 151.0%  
Gross profit margin %22.227.6 80.6%  
Effective tax rate %20.924.8 84.5%   
Net profit margin %14.918.8 78.9%  
BALANCE SHEET DATA
Current assets Rs m19,57711,812 165.7%   
Current liabilities Rs m14,8963,776 394.5%   
Net working cap to sales %11.939.1 30.4%  
Current ratio x1.33.1 42.0%  
Inventory Days Days9077 116.0%  
Debtors Days Days4582 55.6%  
Net fixed assets Rs m27,09714,398 188.2%   
Share capital Rs m377175 214.9%   
"Free" reserves Rs m26,81122,277 120.4%   
Net worth Rs m27,18822,452 121.1%   
Long term debt Rs m4,9937 75,651.5%   
Total assets Rs m47,77826,962 177.2%  
Interest coverage x41.7444.3 9.4%   
Debt to equity ratio x0.20 62,473.3%  
Sales to assets ratio x0.80.8 108.0%   
Return on assets %12.614.4 87.6%  
Return on equity %21.517.2 124.7%  
Return on capital %23.623.0 102.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45310,682 182.1%   
Fx outflow Rs m6,0652,102 288.5%   
Net fx Rs m13,3888,580 156.0%   
CASH FLOW
From Operations Rs m8,1203,748 216.6%  
From Investments Rs m-7,556-2,228 339.1%  
From Financial Activity Rs m590-1,475 -40.0%  
Net Cashflow Rs m1,15345 2,551.5%  

Share Holding

Indian Promoters % 74.1 73.8 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 1.6 187.1%  
FIIs % 9.1 7.6 119.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.0 81.8%  
Shareholders   49,328 20,968 235.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  FDC LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Nov 15, 2019 03:37 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS